Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Micrometastases and isolated tumor cells in breast cancer are indeed associated with poorer outcome.

van Diest PJ, de Boer M, van Deurzen CH, Tjan-Heijnen VC.

J Clin Oncol. 2010 Mar 20;28(9):e140; author reply e141-2. doi: 10.1200/JCO.2009.26.7575. Epub 2010 Feb 16. No abstract available.

PMID:
20159803
2.

Significance of sentinel lymph node micrometastases in patients with breast cancer.

Gyorki DE, Henderson MA.

J Clin Oncol. 2010 Mar 20;28(9):e139; author reply e141-2. doi: 10.1200/JCO.2009.26.1420. Epub 2010 Feb 16. No abstract available.

PMID:
20159811
3.

Breast cancer prognosis and occult lymph node metastases, isolated tumor cells, and micrometastases.

de Boer M, van Dijck JA, Bult P, Borm GF, Tjan-Heijnen VC.

J Natl Cancer Inst. 2010 Mar 17;102(6):410-25. doi: 10.1093/jnci/djq008. Epub 2010 Feb 26. Review.

PMID:
20190185
4.

Prediction of non-SN involvement in patients with SN isolated tumor cells or micrometastases.

Pesce C, Balch C, Jacobs L.

Breast Dis. 2010;31(2):99-106. doi: 10.3233/BD-2010-0301. Review.

PMID:
21368372
5.
6.
7.

[Detailed pathological examination of the sentinel lymph nodes in order to detect micrometastases: no clinical relevance in patients with breast cancer].

Meijnen P, Peterse JL, Nieweg OE, Rutgers EJ.

Ned Tijdschr Geneeskd. 2004 Dec 4;148(49):2428-32. Review. Dutch.

PMID:
15626306
8.

The clinical significance of axillary lymph node micrometastases in breast cancer.

Sakorafas GH, Geraghty J, Pavlakis G.

Eur J Surg Oncol. 2004 Oct;30(8):807-16. Review.

PMID:
15336724
9.

Biological significance of occult micrometastases in histologically negative axillary lymph nodes in breast cancer patients using the recent American Joint Committee on Cancer breast cancer staging system.

Kahn HJ, Hanna WM, Chapman JA, Trudeau ME, Lickley HL, Mobbs BG, Murray D, Pritchard KI, Sawka CA, McCready DR, Marks A.

Breast J. 2006 Jul-Aug;12(4):294-301.

PMID:
16848838
10.

Sentinel node biopsy before neoadjuvant chemotherapy for determining axillary status and treatment prognosis in locally advanced breast cancer.

Cox CE, Cox JM, White LB, Stowell NG, Clark JD, Allred N, Meyers M, Dupont E, Furman B, Minton S.

Ann Surg Oncol. 2006 Apr;13(4):483-90. Epub 2006 Mar 7.

PMID:
16523361
11.
12.
13.

Axillary lymph node dissection for sentinel lymph node micrometastases may be safely omitted in early-stage breast cancer patients: long-term outcomes of a prospective study.

Langer I, Guller U, Viehl CT, Moch H, Wight E, Harder F, Oertli D, Zuber M.

Ann Surg Oncol. 2009 Dec;16(12):3366-74. doi: 10.1245/s10434-009-0660-9. Epub 2009 Sep 4.

PMID:
19760047
14.
16.

Prognostic and therapeutic impact of sentinel node micrometastasis in patients with invasive breast cancer.

Carcoforo P, Bergossi L, Basaglia E, Soliani G, Querzoli P, Zambrini E, Pozza E, Feggi L.

Tumori. 2002 May-Jun;88(3):S4-5.

PMID:
12365385
17.

Expanding indications for lymphatic mapping and sentinel lymph node biopsy in the breast cancer population.

Reintgen D.

Ann Surg Oncol. 2001 Oct;8(9):687. No abstract available.

PMID:
11597007
18.

Minimal disease in sentinel nodes.

Cserni G.

Pathol Oncol Res. 2008 Jun;14(2):117-21. doi: 10.1007/s12253-008-9052-x. Epub 2008 May 21. Review.

PMID:
18493872
19.

[Importance of lymph node involvement in breast carcinoma for the oncologist].

Cerny T.

Zentralbl Chir. 2000;125(10):813-6. German.

PMID:
11098575
20.

The eternally enigmatic axilla: further controversy about axillary lymph nodes in breast cancer.

McMasters KM.

Ann Surg Oncol. 2003 Dec;10(10):1128-30. No abstract available.

PMID:
14654464

Supplemental Content

Support Center